Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29130935 | 0.98 | PARP1 (0.53) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL20653883 | 0.76 | MAPT (0.52) | SMN1; SMN2KDM4EMAPTACVR1LMNA | |
| SCHEMBL7377865 | 0.75 | ACVR1 (0.55) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL13166527 | 0.73 | MAPT (0.48) | PARP1SMN1; SMN2KDM4EMAPTACVR1 | |
| SCHEMBL2938806 | 0.73 | PARP1 (0.56) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL31082754 | 0.72 | KDM4A (0.42) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL17276036 | 0.72 | SMN1; SMN2 (0.49) | PARP1SMN1; SMN2KDM4EMAPTACVR1 | |
| SCHEMBL13166532 | 0.72 | CYP3A4 (0.47) | PARP1KDM4EMAPTACVR1LMNA | |
| SCHEMBL29421129 | 0.72 | PARP1 (0.55) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL13859959 | 0.72 | MAPT (0.71) | KDM4EMAPTACVR1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024663-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | DIGMBIO. INC. (KR) | 2023-01-26 | — | — | US | claimed |
| EP-3337802-A1 | HETEROARYL DERIVATIVES AS PARP INHIBITORS | Lupin Limited (IN) | 2018-06-27 | — | — | EP | claimed |
| WO-2017029601-A1 | HETEROARYL DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2017-02-23 | — | — | WO | claimed |
| US-7750151-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | claimed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | claimed |
| EP-1737861-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005100356-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | claimed |
| US-5391554-A | Antitumor agent | WARNER-LAMBERT COMPANY (US) | 1995-02-21 | — | — | US | claimed |
| WO-1994005664-A1 | NAPHTHYRIDINES AS POTENTIATORS OF LETHAL EFFECTS OF RADIATION ON TUMOUR CELLS | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | claimed |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003057695-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2001091796-A2 | METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-5391554-A | Antitumor agent | WARNER-LAMBERT COMPANY (US) | 1995-02-21 | — | — | US | disclosed |
| WO-1994005664-A1 | NAPHTHYRIDINES AS POTENTIATORS OF LETHAL EFFECTS OF RADIATION ON TUMOUR CELLS | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280899-A1 | Inhibitors of Akt Activity | AKT1, AKT2, AKT3 | PARP1 852/4885PDPK1 18/4885CA12 3273/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | PARP1 1/4885PDPK1 119/4885CA12 4051/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | PARP1 1538/4885PDPK1 1305/4885CA12 4442/4885 |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | PARP1, PARP2, PARP11 | PARP1 1/4885PDPK1 56/4885CA12 4873/4885 |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | PARP1 1287/4885PDPK1 127/4885CA12 4867/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | PARP1 2620/4885PDPK1 321/4885CA12 4024/4885 |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | TALDO1, TBCA, TBCD | PARP1 2559/4885PDPK1 1248/4885CA12 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.